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for Sweden [1]. Sensitivity analysis was associated with ICERs ranging up to SEK 
900,000 (c93,856) per QALY gained. CONCLUSIONS: Due to the data limitations, 
HE modeling in the orphan drug setting is challenging. Analysis could be performed 
as requested by Sweden’s Dental and Pharmaceutical Beneﬁ ts Agency (TLV), however, 
providing evidence that health beneﬁ ts can provide good value for money even for an 
orphan population. DLI received a positive reimbursement recommendation by the 
TLV. [1] Persson U, Hjelmgren J (2003).
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COST-UTILITY ANALYSIS OF ROTIGOTINE TRANSDERMAL PATCH IN 
EARLY-STAGE PARKINSON’S DISEASE IN SCOTLAND
Benhaddi H, Gunn A
UCB Pharma S.A., Brussels, Belgium
OBJECTIVES: To evaluate the cost-effectiveness of rotigotine transdermal patch as 
monotherapy in early-stage Parkinson’s disease (PD) compared to ropinirole and other 
dopamine agonists (DA) from the NHS perspective in Scotland. METHODS: a deci-
sion-analytic model was developed, based on treatment of an early-stage PD patient 
(Hoehn and Yahr-stage 2); treatment arms were rotigotine, ropinirole, and a DA 
practice comparator including ropinirole, cabergoline and pramipexole. 5-year and 
10-year time horizons were considered for patients who remained on monotherapy 
only. The economic evaluation is a cost-utility analysis with health outcomes expressed 
in Quality Adjusted Life-years (QALY) gained in 2006. Costs relating to drug acquisi-
tion, PD severity, falls, occurrence of motor complications and other complications/
adverse events/co-morbidities were considered in the model. Efﬁ cacy and safety data 
were estimated with a meta-analysis. Quality of life was measured using EQ-5D. Data 
on medical resource use was obtained via expert interviews and literature review. 
Costs and effects were discounted at the rate of 3.5%. RESULTS: After 5 years, treat-
ment with rotigotine transdermal patch resulted in an estimated 2.30 QALYs, slightly 
higher than with ropinirole (2.26) and the DA practice comparator (2.27). 10-year 
outcomes were 3.22, 3.17 and 3.17 QALYs for rotigotine, ropinirole and DA practice 
comparator, respectively. Total costs for rotigotine, ropinirole and DA practice com-
parator were £34,748, £37,694 and £36,459 respectively after 5 years and £79,477, 
£84,120 and £81,631, respectively after 10 years. With a willingness-to-pay of 
£20,000 per QALY gained, there is a 90% probability that rotigotine is cost-effective 
relative to ropinirole, and a 85% probability of cost-effectiveness relative to the DA 
practice comparator for both 5-year and 10-year time horizons. CONCLUSIONS: 
Based on the model, rotigotine may be considered a dominant strategy over ropinirole 
and DA practice comparator in the treatment of early-stage PD at 5-year and 10-year 
time horizons.
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COST-UTILITY ANALYSIS OF RIZATRIPTAN VERSUS (GENERIC) 
SUMATRIPTAN IN SWEDEN
Lundberg J1, Golden WM2, Insinga RP3
1MSD Sweden, Sollentuna, Sweden; 2Merck & Co., Inc., Whitehouse Station, NJ, USA; 
3Merck & Co., Inc., Upper Gwynedd, PA, USA
OBJECTIVES: In 2005 the Swedish pharmaceutical beneﬁ ts board published a review 
concluding that rizatriptan 10  mg was one of the most cost-effective triptans for 
treating migraine, although efﬁ cacy differences among the triptan class were generally 
small. However, since the review, the price of sumatriptan has declined due to generic 
product entry. In this study, we sought to investigate the cost-effectiveness of rizat-
riptan versus generic sumatriptan. METHODS: A published Canadian decision-ana-
lytic model (Thompson et al., Pharmacoeconomics 2005) was adapted to estimate 
treatment costs and effects of rizatriptan 10 mg versus (generic) sumatriptan in a single 
migraine attack over a 24-hour time-frame in Sweden. Values modiﬁ ed from the 
published model were the substitution of Swedish health care and productivity costs, 
and updated data on 2-hour and 2–24 hour pain freedom (including results from more 
recent head-to-head trials of the comparators). As both sumatriptan 50 mg and 
100 mg are marketed in Sweden, and have comparable efﬁ cacy proﬁ les, averaged data 
for the two doses were used as a comparator to rizatriptan 10 mg. RESULTS: From 
a societal perspective, including both health care and productivity costs, the compari-
son of rizatriptan 10 mg versus (generic) sumatriptan resulted in cost-savings of ~ 5 
SEK, and greater QALYs for rizatriptan 10 mg. Inclusion of health care costs only, 
yielded a cost-effectiveness ratio for rizatriptan vs. sumatriptan of 343,929 SEK/
QALY. CONCLUSIONS: Given the data and assumptions used, in a single attack 
model, rizatriptan 10 mg was found to have a cost-effectiveness ratio compared to 
(generic) sumatriptan within the range typically regarded as cost-effective in Sweden. 
These ﬁ ndings suggest that there is reason to explore the cost-effectiveness of phar-
maceutical and other medical interventions with large differences in acquisition cost 
even though efﬁ cacy differences may appear to be small.
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COST-UTILITY ANALYSIS OF LACOSAMIDE ADJUNCTIVE THERAPY IN 
THE TREATMENT OF PARTIAL-ONSET SEIZURES IN EPILEPTIC 
PATIENTS IN BELGIUM
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OBJECTIVES: This study aims at evaluating the incremental cost-effectiveness ratio 
(ICER) for lacosamide compared with standard therapy alone from the perspective of 
the Belgian health care payer in 2010. METHODS: A decision tree simulating the 
treatment pathway of a hypothetical cohort of 1,000 patients over two years was split 
into four phases of six months each during which patients can become seizure free, 
experience a seizure reduction (deﬁ ned as ≥50% reduction in seizures), or withdraw 
due to non-response. The antiepileptic drugs (AEDs) included in the standard therapy 
arm were extracted from the pivotal trials and included carbamazepine, lamotrigine, 
levetiracetam, topiramate and valproate. Health state probabilities, seizure frequency 
and utility values were taken from lacosamide trials or from the literature. Costs of 
general practitioner visits, outpatient visits, hospitalizations and emergency depart-
ment visits were included. Resource use was estimated by a Belgian panel of eight 
neurologists. Costs were discounted at a rate of 3% and consequences at a rate of 
1.5%. RESULTS: Over a 24-month period, standard AED therapy plus lacosamide 
led to a reduction of 7 seizures, an increase of 0.038 quality-adjusted life-years, and 
a cost decrease of c3619 per patient as compared with standard therapy alone. Results 
were also calculated for a 6-, 12- and 18-month follow-up. Lacosamide plus AED 
therapy dominated versus standard therapy alone. Using a willingness to pay of 
c30,000 per quality-adjusted life-year, the net monetary beneﬁ t of standard antiepi-
leptic drug therapy plus lacosamide amounted to c4,754. The probability of standard 
AED therapy plus lacosamide being cost-effective was 97.3% at 6 months, 99.8% at 
12 months, 99.9% at 18 months, and 100% at 24 months. CONCLUSIONS: In 
epileptic patients who are difﬁ cult to treat with other AEDs, standard AED therapy 
plus lacosamide appears to be a cost-effective alternative. 
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IMPACT OF AN ADHERENCE PROGRAM, RUN AS A TELEPHONE 
INTERVENTION ON COMPLIANCE WITH SUBCUTANEOUS 
INTERFERON Â-1A FOR MULTIPLE SCLEROSIS PATIENTS USING A 
MAIL-ORDER PHARMACY
Papademetriou E1, Levin R1, Tuennermann M2, Lammers V2, Aubert RE1
1Medco Health Solutions, Franklin Lakes, NJ, USA; 2Europa Apotheek Venlo B.V., Venlo, The 
Netherlands
OBJECTIVES: Quasi-experimental analysis to determine the effect of an opt-in tele-
phone intervention on adherence in patients using subcutaneous interferon β-1a, 
which is indicated for relapsing-remitting multiple sclerosis. Drop-out reasons, side-
effects, and expectations of therapy are described. METHODS: Customers of a mail-
order pharmacy that services Germany who ordered subcutaneous interferon β-1a 
were targeted for enrollment in a free program that included an initial counseling call, 
optional e-mail reminders for the next doctor’s consultation and prescription, and 
ongoing counseling calls. Patients enrolled in the program for at least 6-months were 
included in the analysis and compared to patients that did not enter the program over 
the same time period. Proportion of days covered (PDC) was calculated for each group 
and compared using analysis of variance. Enrollees in the program were administered 
a questionnaire at the initial welcome call addressing their expectations of therapy, 
and again during each counseling call regarding their compliance behavior, and side 
effects. RESULTS: Patients in the adherence program showed an unadjusted PDC 
8.2% higher than the control, F(1.247) = 13.44, p = 0.0003. One program patient 
switched drugs compared to six control group patients. a total of 21% of enrolled 
subjects reported missing at least one dose. Side-effects included pain/inﬂ ammation at 
the site of injection (24.41%), fatigue (20.73%), headaches (17.06%), and ﬂ u-like 
symptoms (9.71%). Exacerbations were reported by 15.7% of patients. Patients’ had 
expectations that therapy would prolong the distance between exacerbations (23.36%) 
and slow the progression of disability due to the disease (21.28%). CONCLUSIONS: 
Actively recruiting patients into an optional adherence program signiﬁ cantly increased 
the compliance rate for relapsing-remitting multiple sclerosis patients using subcutane-
ous interferon β-1a. Side effects experienced by enrolled patients were consistent with 
the package insert. Limitations include a potential bias between patients that agree to 
the program vs. those that do not, as well as the lack of additional questionnaire data 
from the control group.
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EPILEPTIC DRUGS IN SOUTH AFRICA
Van Zyl T, Lubbe MS, Serfontein JHP, Rakumakoe DM
North-West University, Potchefstroom, South Africa
OBJECTIVES: To investigate the possible inﬂ uence of age on the reﬁ ll-based adher-
ence rates of anti-epileptic drugs. METHODS: A retrospective drug utilization review 
was performed on medicine claims data of a pharmacy beneﬁ t management company 
in South Africa. Reﬁ ll-based adherence rates were calculated for 64,457 anti-epileptic 
drugs that were prescribed more than once during a four-year period (January 1, 2005 
to December 2008). The reﬁ ll-based adherence rate was calculated per trade name by 
using the following equation: Reﬁ ll-Adherence rate = (total number of days of anti-
epileptic drugs supplied—days supplied at the last reﬁ ll)/(date last claimed—date ﬁ rst 
claimed). [RSA Rand (R)/$US = 6.38112 (2005); 6.78812 (2006); 7.06926 (2007) and 
8.27505 (2008)]. RESULTS: Only 30.5% (n = 19 635) of anti-epileptic drugs had 
reﬁ ll-adherence rates between between 90% and 110%. The majority of anti-epileptic 
drugs (58.9%; n = 37 962) had reﬁ ll-adherence rates below 90% that accounted for 
39.2% (n = R 57 599 838) of the total cost of all anti-epileptic drugs (N = R146 863 
755) included in these calculations. Anti-epileptic drugs with reﬁ ll-adherence rates 
>110% (10,7%; n = 6 860) accounted for 6.7% (R9 782 864) of the total cost of all 
anti-epileptic drugs. The average reﬁ ll-adherence rate decreased with nearly 10% from 
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93.7% in age group 1 (0 ≤ 12 years) to 83.3% in age group 5 (older than 65 years). 
In general the lowest average reﬁ ll-based adherence rates were obtained with medicine 
items containing phenobarbitone and vitamin B1 (52.0% ± 37.8); phenobarbitone 
(63.5% ± 47.2); primidone metabolites (69.7% ± 47.2%); clonazepam (77.8% ± 
184.8) and carbamazepine (80.9% ± 151.1) CONCLUSIONS: Most of the anti-epi-
leptic drugs had unacceptable low reﬁ ll-adherence rates. Reﬁ ll-adherence rates of 
anti-epileptic drugs decreased with an increase in the age of patients.
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REFILL-ADHERENCE RATES OF ANTIPARKINSON MEDICATION IN THE 
PRIVATE HEALTH CARE SECTOR OF SOUTH AFRICA
Van der Merwe S, Lubbe MS, Du Plessis JM, Bekker E
North-West University, Potchefstroom, South Africa
OBJECTIVES: To investigate the prevalence of unacceptable reﬁ ll-based adherence 
rates with antiparkinson medicine items. METHODS: A retrospective drug utilization 
study was performed on medicine claims data of a pharmacy beneﬁ t management 
company in South Africa during January 1, 2005 until December 31, 2008. Reﬁ ll-
based adherence rates were calculated for 8 768 antiparkinson medicine items that 
were prescribed more than once during a four-year period (January 1, 2005 to Decem-
ber 2008). The reﬁ ll-based adherence rate was calculated per trade name by using the 
following equation: Reﬁ ll-Adherence rate = (total number of days of antiparkinson 
medicine items supplied—days supplied at the last reﬁ ll)/(date last claimed—date ﬁ rst 
claimed). (RSA Rand(R)/$US = 6.8595 on 31 Dec. 2007). [RSA Rand (R)/$US = 
6.38112 (2005); 6.78812 (2006); 7.06926 (2007) and 8.27505 (2008)] RESULTS: A 
majority of antiparkinson medicine items (53.50%, n = 4,691) had unacceptably low 
reﬁ ll-adherence rates below 90%, that accounted for 41.62% (n = R16,398,512.00) 
of the total cost (N = R39,402,898.20) of all antiparkinson medicine items included 
in this study. Only 36.78% (n = 3225) of antiparkinson medicine items had acceptable 
reﬁ ll-adherence rates between 90% and 110%. Those with unacceptable high reﬁ ll-
adherence rates accounted for 9.72% (n = 852) of all antiparkinson medicine items 
and represented 6.5% (n = R2,574,597) of the total cost. No practical signiﬁ cant 
difference in the average reﬁ ll-adherence rates was found between male (93.99% ± 
186.99) and female (90.83% ± 175.21) patients. Biperidien, carbidopa/levodopa, and 
levodopa/benserazide containing products had on average unacceptable low reﬁ ll-
adherence rates (<90%). CONCLUSIONS: Although poor obedience to treatment 
schedules adds up to aggravation of Parkinson’s disease leading to death and ampliﬁ ed 
health care cost, it seems that the reﬁ ll-adherence rate of antiparkinson medicine items 
is not very favourable
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A PSYCHOMETRIC EVALUATION OF THE REVISED SCOPA DIARY 
CARD IN PARKINSON’S DISEASE PATIENTS
Buck PO1, Castelli-Haley J1, White RE1, Rendas-Baum R2, White MK2
1Teva Neuroscience, Kansas City, MO, USA; 2QualityMetric Incorporated, Lincoln, RI, USA
OBJECTIVES: The Scales for Outcomes in Patients with Parkinson’s disease Diary 
Card (SCOPA-DC) is a daily diary designed to measure motor impairment in Parkin-
son’s disease (PD) patients with ﬂ uctuating symptoms. Previous qualitative research 
evaluated the content validity of the SCOPA-DC in the US and expanded it to measure 
non-motor symptoms. The current research examined the psychometric properties of 
the revised SCOPA-DC. METHODS: A sample of adults age 30 and older with self-
reported doctor-conﬁ rmed PD were recruited, screened, and consented online from a 
Knowledge Networks panel. Eligible patients were mailed a study packet that con-
tained the revised SCOPA-DC as well as a training video. The revised SCOPA-DC 
included 7 non-motor items: fatigue, memory, anxiety, pain, difﬁ culty swallowing, 
frequent urination, and sweating. The diary was completed 7 times per day for 3 
consecutive days. Consistent with the original SCOPA-DC, 3-day scores were calcu-
lated for each item. Higher scores indicated greater symptom severity. RESULTS: A 
total of 101 PD patients completed and returned the revised SCOPA-DC. The sample 
was 50.5% male and had been diagnosed with PD for an average of 7.4 years. Fre-
quency distributions showed little missing data (approximately 1.0%), although items 
were generally right-skewed. Fatigue (29.4) and walking (28.7) had the highest mean 
scores; sweating (7.3) and difﬁ culty swallowing (9.7) had the lowest mean scores. 
Factor analysis supported a 3-factor solution: mobility, physical functioning, and 
psychological functioning. These factors demonstrated good internal consistency 
(alpha = 0.83–0.87) and correlations with health-related quality of life instruments 
were suggestive of construct validity. CONCLUSIONS: In this US sample of PD 
patients with varied disease severity, the revised SCOPA-DC exhibited good psycho-
metric properties, including evidence of reliability and validity. Furthermore, patients 
reported that the revised SCOPA-DC was clear and easy to complete. The revised 
SCOPA-DC holds promise for measuring a broad spectrum of ﬂ uctuating motor and 
non-motor PD symptoms.
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COMPARISON OF ANALYIC HIERARCHY PROCESS AND CONJOINT 
ANALYSIS METHODS IN ASSESSING TREATMENT ALTERNATIVES IN 
STROKE REHABILITATION
Ijzerman M1, Bridges JF2, Van Til J1
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MD, USA
OBJECTIVES: There has been increasing interest novel HTA methods that will incor-
porate patient preferences in a more transparent and scientiﬁ cally valid way. The 
fundamental problem of the assessment of beneﬁ ts in HTA is the identiﬁ cation, 
ranking and valuation of multiple health care outcomes. We used two multi-criteria 
methods to rank and value ﬁ ve different treatments in stroke rehabilitation. Analytic 
Hierarchy Process (AHP) stems from operations research and is increasingly being 
used in health care to weigh patient-reported endpoints. Conjoint analysis (CA) is a 
stated preference method that often takes the discrete choice format. In CA, hypotheti-
cal scenarios are used to generate part-worth utilities for attributes. METHODS: To 
determine the clinical decision context and related criteria, a paper-and-pencil ques-
tionnaire was conducted among a sample of Dutch physiatrists united in a stroke 
interest group. From the lists of criteria (e.g. clinical beneﬁ t, impact of treatment) an 
expert panel deﬁ ned the AHP decision structure as well as the conjoint analysis survey 
format. Finally, the complete questionnaire including the AHP and CA survey was 
sent out to 184 patients with ankle-foot impairments. Eventually, 89 patients com-
pleted both surveys. RESULTS: On average, the prediction of preferred treatment on 
a group level is similar for both AHP and CA. However. on an inidividual level there 
seems to be more variation in treatment preference. Using AHP weights, a vast major-
ity preferred soft-tissue surgery where most patients preferred orthopedic shoes if CA 
weights were used. This may have been caused by labelling effects of the attributes. 
CONCLUSIONS: Both methods have there pros and cons in ranking and valuing 
patient-reported endpoints. Of the methods AHP is relatively easy to apply. In predic-
tion of overall outcome, both methods perform equally. However, for individual 
treatment preference we observed some differences. It may be concluded that the 
decision structure, framing and labelling of the treatment attributes are more impor-
tant than the speciﬁ c elicitation method used.
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HEALTH STATUS COMPARISON BETWEEN STABLE PARKINSON’S 
DISEASE PATIENTS AND THOSE EXPERIENCING OFF-TIME
Buck PO1, White RE1, Castelli-Haley J1, Rendas-Baum R2, White MK2
1Teva Neuroscience, Kansas City, MO, USA; 2QualityMetric Incorporated, Lincoln, RI, USA
OBJECTIVES: End-of-dose wearing-off is commonly experienced by Parkinson’s 
disease (PD) patients who have used dopaminergic therapy for several years. Although 
investigations of wearing-off have traditionally focused on motor ﬂ uctuations, it is 
increasingly recognized that non-motor symptoms also vary between periods of “ON” 
(when PD symptoms are minimized due to medication) and “OFF” (when PD symp-
toms return). This study characterizes the self-reported health status of PD patients 
who experienced OFF-time as compared to those who were stable. METHODS: 
Recruited from an online panel maintained by Knowledge Networks, adults with 
self-reported doctor-conﬁ rmed PD were screened, consented, and completed a cross-
sectional survey. Frequency of OFF-time was measured using the Uniﬁ ed Parkinson’s 
Disease Rating Scale Part IV. Demographics, PD-speciﬁ c characteristics, the 9-item 
Wearing-off Questionnaire (WOQ-9), the Short Form-12v2 (SF-12), and the Parkin-
son’s Disease Questionnaire-8 (PDQ-8) were also assessed. RESULTS: Data were 
available for 165 PD patients (mean age = 66.6 years; 52.7% male; mean time from 
diagnosis = 7.1 years). Twenty-ﬁ ve (15%) of the patients reported experiencing no 
OFF-time on a typical day and were classiﬁ ed as stable; the remaining 85% reported 
experiencing OFF-time. There were few signiﬁ cant differences between the two groups 
in terms of demographics and PD history. Compared to those experiencing OFF-time, 
stable patients reported fewer motor and non-motor wearing-off symptoms based on 
the WOQ-9 (P < 0.05), as well as better health on the Physical and Mental Component 
Summary scores of the SF-12 (P < 0.05) and the Summary Index score of the PDQ-8 
(P < 0.01). CONCLUSIONS: PD patients who experienced at least some OFF-time 
on a typical day reported worse overall physical and mental well-being than stable 
patients. Furthermore, both motor and non-motor wearing-off symptoms differed 
between the two patient groups. Additional research to understand the consequences 
of OFF-time would be useful, especially as it pertains to non-motor symptoms.
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PATIENT AND PHYSICIAN GLOBAL PERCEPTION OF LEVODOPA/
CARBIDOPA/ENTACAPONE VS. LEVODOPA/CARBIDOPA IN PATIENTS 
WITH PARKINSON’S DISEASE EXPERIENCING EARLY WEARING-OFF
Ruyra J1, Balañá M1, Lahoz R1, Hernandez B2, Tolosa E2
1Novartis Farmacéutica S.A., Barcelona, Spain; 2Hospital Clínic de Barcelona, Barcelona, Spain
OBJECTIVES: To compare patients’ and physicians’ global perceptions of Parkinson’s 
disease (PD) in two treatment groups: levodopa/carbidopa/entacapone (LCE) vs. 
levodopa/carbidopa (LC). METHODS: Multicentre, double-blind, randomised phase 
IV study. Ninety-ﬁ ve PD patients with early wearing-off (WO) and deterioration of 
activities of daily living (ADLs) were randomised to receive LCE (n = 46) or LC (n = 
49) with a 3-month follow-up. Patient and physician global perception of PD was 
assessed at the end of the study. The PDQ-39 quality of life (QoL) questionnaire, and 
the longitudinal course of PD using the different parts of UPDRS (part I, part II, part 
III, and IV) were evaluated along the study. Differences between health improvement 
by patient and physician were analyzed by the Mann Whitney U-test. The mean dif-
ferences from baseline to ﬁ nal visit in PDQ-39 and in UPDRS (part I, II, IIII IV) score 
were analyzed by an ANCOVA model. RESULTS: Mean (SD) age was 66.4 ± 8.6 
years and 50.0% were women. Half percent of patients showed stage II according to 
the Hoehn and Yahr classiﬁ cation. Patient global perception showed a signiﬁ cant 
better score in the LCE than in LC group (−0.9 ± 1.0 LCE and −0.4 ± 1.17 LC, p = 
0. 0291). Similar results were obtained by the physician (−0.3 ± 0.8 vs. −0.4, p = 0. 
0017). The adjusted mean differences in the PDQ-39 showed a trend for a higher 
improvement in QoL in the LCE group (6.3 ± 20.4 vs. 0.81 ± 15.6), although did not 
reach statistical signiﬁ cance. The UPDRS evaluation showed a signiﬁ cant higher 
